

Giovanni Palermo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6794593/publications.pdf>

Version: 2024-02-01

52
papers

985
citations

430754

18
h-index

477173

29
g-index

52
all docs

52
docs citations

52
times ranked

1669
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Compensatory Mechanisms in <sc>LRRK2</sc> Mutation Carriers. <i>Movement Disorders</i> , 2022, 37, 662-663.	2.2	0
2	Negative <sc>DAT</sc> SPECT in Old Onset Parkinson's Disease: An Additional Pitfall?. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 530-534.	0.8	1
3	Fluid Biomarkers in Alzheimer's Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments. <i>Diagnostics</i> , 2022, 12, 796.	1.3	4
4	Essential tremor and cognitive impairment: who, how, and why. <i>Neurological Sciences</i> , 2022, 43, 4133-4143.	0.9	3
5	Prevalence and impact of COVID-19 in Parkinson's disease: evidence from a multi-center survey in Tuscany region. <i>Journal of Neurology</i> , 2021, 268, 1179-1187.	1.8	70
6	Connected speech in progressive supranuclear palsy: a possible role in differential diagnosis. <i>Neurological Sciences</i> , 2021, 42, 1483-1490.	0.9	3
7	Aptamer prediction of brain amyloid- β status in cognitively normal individuals at risk for Alzheimer's disease. <i>PLoS ONE</i> , 2021, 16, e0243902.	1.1	5
8	MiRNA-15b and miRNA-125b are associated with regional A β -PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. <i>Translational Psychiatry</i> , 2021, 11, 78.	2.4	13
9	Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2021, 18, 27-48.	1.3	8
10	Mild Cognitive Impairment in de novo Parkinson's Disease: Selective Attention Deficit as Early Sign of Neurocognitive Decay. <i>Frontiers in Psychology</i> , 2021, 12, 546476.	1.1	2
11	β -Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 885-893.	1.2	9
12	Understanding the Multiple Role of Mitochondria in Parkinson's Disease and Related Disorders: Lesson From Genetics and Protein-Protein Interaction Network. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 636506.	1.8	44
13	Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson's Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2302.	1.0	8
14	Statins in Parkinson's Disease: Influence on Motor Progression. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1651-1662.	1.5	8
15	Dissecting the Interplay Between Time of Dementia and Cognitive Profiles in Lewy Body Dementias. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 757-766.	1.2	1
16	Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11234.	1.8	19
17	Statins in Parkinson's disease: Influence on motor progression. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119502.	0.3	0
18	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. <i>Neurology</i> , 2020, 94, e30-e41.	1.5	20

#	ARTICLE	IF	CITATIONS
19	Extended release levodopa at bedtime as a treatment for nocturia in Parkinson's disease: An open label study. <i>Journal of the Neurological Sciences</i> , 2020, 410, 116625.	0.3	13
20	β -Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 130.	3.0	16
21	The role of synaptic biomarkers in the spectrum of neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2020, 17, 543-559.	1.3	16
22	Association of plasma YKL-40 with brain amyloid- β levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 96, 22-32.	1.5	18
23	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 147.	3.0	23
24	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2020, 57, 4667-4691.	1.9	33
25	Impact of <sc>Coronavirus Disease 20</sc>19 Pandemic on Cognition in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1717-1718.	2.2	30
26	Red blood cell α -synuclein heteroaggregates can discriminate healthy controls from cognitively impaired subjects of the AD-LBD spectrum. <i>Alzheimer's and Dementia</i> , 2020, 16, e040618.	0.4	0
27	In vivo assessment of the noradrenergic nucleus locus coeruleus in Alzheimer's disease and other types of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e043616.	0.4	0
28	Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications. <i>Journal of Neurology</i> , 2020, 267, 2949-2960.	1.8	26
29	Dopamine Transporter, Age, and Motor Complications in Parkinson's Disease: A Clinical and Single-Photon Emission Computed Tomography Study. <i>Movement Disorders</i> , 2020, 35, 1028-1036.	2.2	17
30	Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between α -synucleinopathies. <i>Journal of Neurology</i> , 2020, 267, 3444-3456.	1.8	17
31	Theory of mind in Parkinson's disease: evidences in drug-naïve patients and longitudinal effects of dopaminergic therapy. <i>Neurological Sciences</i> , 2020, 41, 2761-2766.	0.9	4
32	SLC25A46 mutations in patients with Parkinson's Disease and optic atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 1-5.	1.1	16
33	Tardive Syndrome Associated With Tetrabenazine in Huntington Disease. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 628-630.	0.7	2
34	Brain β load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2019, 15, 1274-1285.	0.4	25
35	Molecular Imaging of the Dopamine Transporter. <i>Cells</i> , 2019, 8, 872.	1.8	62
36	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019, 83, 42-53.	1.5	48

#	ARTICLE	IF	CITATIONS
37	Clinical Correlates of Cerebral Amyloid Deposition in Parkinson's Disease Dementia: Evidence from a PET Study. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 597-609.	1.2	13
38	Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 615-629.	1.2	44
39	A frontline defense against neurodegenerative diseases: the development of early disease detection methods. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 559-563.	1.5	12
40	The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. <i>Expert Review of Proteomics</i> , 2019, 16, 593-600.	1.3	41
41	Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 764-775.	0.4	122
42	Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 940-950.	0.4	43
43	Freezing of gait and dementia in parkinsonism: A retrospective case-control study. <i>Brain and Behavior</i> , 2019, 9, e01247.	1.0	8
44	Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome. <i>Brain and Behavior</i> , 2019, 9, e01182.	1.0	5
45	COMMENTARY: DEVELOPMENT OF THE BLOOD-BASED ALZHEIMER'S DISEASE LIQUID BIOPSY. <i>Journal of prevention of Alzheimer's disease</i> , The, 2019, 6, 1-3.	1.5	3
46	Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology. <i>Frontiers in Pharmacology</i> , 2019, 10, 310.	1.6	35
47	Advances in the pharmacotherapeutic management of dementia with Lewy bodies. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1643-1653.	0.9	9
48	Brain-Derived Neurotrophic Factor (BDNF) and Serotonin Transporter (SERT) in Platelets of Patients with Mild Huntington's Disease: Relationships with Social Cognition Symptoms. <i>Archives Italiennes De Biologie</i> , 2018, 156, 27-39.	0.1	15
49	Antipsychotic drugs in Huntington's disease. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 227-237.	1.4	27
50	Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 81-84.	1.1	24
51	D5-Oxytocin plasma levels as predictor of social cognition in huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A35.2-A35.	0.9	0
52	F5-Social cognition in huntington's disease: evidence from a prospective study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A50.1-A50.	0.9	0